PDCD1 and triple-negative breast carcinoma: (118) found that PD-1 and LAG-3 were simultaneously expressed on tumor-infiltrating lymphocytes in approximately 15% of triple-negative breast cancer patients, providing an opportunity to evaluate anti-LAG and anti-PD-1/PD-L1.